[Director of the National Medical Insurance Administration Zhang Ke: This year, two commercially insured innovative drug catalog drugs were successfully included in the basic medical insurance catalog] On November 14, reporters learned from the 2026 High-Quality Development Conference on Innovative Drugs held today that Zhang Ke, director of the National Medical Insurance Administration, said that from the launch of the commercially insured innovative drug catalog last year to the establishment of a linkage mechanism between basic medical insurance and commercially insured innovative drug catalog this year, the multiple payment paths for innovative drugs have been further expanded. This year, two commercially insured innovative drug catalog drugs have been successfully included in the basic medical insurance catalog, and it has been clarified that relevant exclusion support policies still apply to further provide protection for clinical use. Zhang Ke said that in the past year, the medical insurance department has continued to launch a series of measures around innovative drug access and payment mechanisms, including conducting pre-communications on reference drugs, exploring pre-application mechanisms, optimizing pre-negotiations on innovative drug prices, and exploring pre-approval of innovative drugs and medical services, etc., to help companies clarify market positioning and price expectations in advance, and create conditions for innovative drugs to enter medical insurance access and clinical application as soon as possible after approval. Regarding the next step, Zhang Ke said that the National Medical Insurance Administration will continue to make efforts in six aspects, including providing stable and reliable financial support, building a scientific and reasonable price system, improving the full life cycle value evaluation of innovative drugs, optimizing medical insurance payment policies, providing true and accurate data support, and integrating more payment channels. (Reporters Lu Afeng and Yu Miao)